Go online to PeerView.com/KQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The use of asparaginase, including E coli- and Erwinia-derived compounds, remains an important component of pediatric acute lymphoblastic leukemia (ALL) care, and its use has consistently improved survival outcomes—are you up to the challenge of developing modern regimens that ensure appropriate exposure to asparaginase? In this PeerView CME activity, based on a live “Clinical Consults” symposium at the 2022 ASPHO conference, Drs. Stuart S. Winter and Reuven Schore address the challenges of clinical decision-making with asparaginase compounds as part of pediatric ALL therapy, focusing on topics such as the management of E coli-derived asparaginase hypersensitivity or silent inactivation, preventing discontinuation/truncation, and the integration of novel Erwinia formulations when E coli-derived asparaginase discontinuation occurs. Tune in to learn how to adapt your practice to reflect the innovative science supporting the use of modern asparaginase compounds in pediatric ALL. Upon completion of this activity, participants should be better able to: Describe the clinical ramifications of Escherichia coli asparaginase hypersensitivity and asparaginase discontinuation in pediatric acute lymphoblastic leukemia (ALL), Cite efficacy and safety evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations as a component of multi-agent chemotherapy for pediatric ALL, Implement strategies to overcome barriers to the effective use of asparaginase in pediatric ALL, including the use of appropriate monitoring and management for hypersensitivity, mitigation for infusion reactions, and the integration of novel Erwinia asparaginase compounds into treatment plans.